Publications by authors named "Alexandru-Teodor Zaharie"
Circulating tumor cells (CTCs) are an established prognostic marker in metastatic prostate cancer (PrC) but have received little attention in localized high-risk disease. Peripheral blood was obtained from patients with early intermediate and high-risk PrC (n = 15) at baseline, after radiotherapy, and during follow-up, as well as from metastatic PrC patients (n = 23). CTCs were enriched using the microfluidic Parsortix technology.
View Article and Find Full Text PDFArticle Synopsis
- The emergence of immunotherapies, including CAR T-cell therapy, monoclonal antibodies, and vaccines, has significantly changed how various cancers are treated.* -
- A systematic review was conducted to explore the benefits and challenges of CAR T-cell therapy specifically for prostate cancer, resulting in 26 out of 183 records being deemed eligible.* -
- The review highlights the complexity of the tumor microenvironment in prostate cancer, which plays a crucial role in the effectiveness of immunotherapy treatments.*
Purpose: To retrospectively evaluate the biochemical no evidence of disease (bNED) and late side effects after adjuvant radiotherapy in prostate cancer patients.
Methods: Patients (n = 85) treated with external beam radiotherapy between 1997 and 2013 following radical prostatectomy (RPE) with pathological tumour stage pT2c with positive surgical margins or pT3 and pT4 tumours with or without positive margins who presented with a postoperative and a preradiation prostate-specific antigen (PSA) level below 0.1 ng/ml.
Thymoma and thymic carcinoma are thymic epithelial tumors (TETs). We performed a molecular profiling to investigate the pathogenesis of TETs and identify novel targets for therapy. We analyzed 37 thymomas (18 type A, 19 type B3) and 35 thymic carcinomas.
View Article and Find Full Text PDF